NCT02314247 · MORE INFO

Limitations, agreements, and source contact

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma · Source last updated 2023-01-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: Due to unexpectedly slow recruitment, the Sponsor decided to terminate the study after 16 patients had been enrolled. The small study population limits the evaluation of both efficacy and safety of selinexor in patients with PTCL or CTCL.

point Of Contact

email: jshah@karyopharm.com
organization: Karyopharm Therapeutics Inc.
phone: (617) 658-0600
title: Jatin Shah, MD

Complete source fields

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: true

limitations And Caveats

description: Due to unexpectedly slow recruitment, the Sponsor decided to terminate the study after 16 patients had been enrolled. The small study population limits the evaluation of both efficacy and safety of selinexor in patients with PTCL or CTCL.

point Of Contact

email: jshah@karyopharm.com
organization: Karyopharm Therapeutics Inc.
phone: (617) 658-0600
title: Jatin Shah, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice